A model of persistent post SARS-CoV-2 induced lung disease for target identification and testing of therapeutic strategies
Abstract COVID-19 survivors develop post-acute sequelae of SARS-CoV-2 (PASC), but the mechanistic basis of PASC-associated lung abnormalities suffers from a lack of longitudinal samples. Mouse-adapted SARS-CoV-2 MA10 produces an acute respiratory distress syndrome (ARDS) in mice similar to humans. To investigate PASC pathogenesis, studies of MA10-infected mice were extended from acute disease through clinical recovery. At 15-120 days post-virus clearance, histologic evaluation identified subpleural lesions containing collagen, proliferative fibroblasts, and chronic inflammation with tertiary lymphoid structures. Longitudinal spatial transcriptional profiling identified global reparative and fibrotic pathways dysregulated in diseased regions, similar to human COVID-19. Populations of alveolar intermediate cells, coupled with focal upregulation of pro-fibrotic markers, were identified in persistently diseased regions. Early intervention with antiviral EIDD-2801 reduced chronic disease, and early anti-fibrotic agent (nintedanib) intervention modified early disease severity. This murine model provides opportunities to identify pathways associated with persistent SARS-CoV-2 pulmonary disease and test countermeasures to ameliorate PASC..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 17. Feb. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2022.02.15.480515 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI03525758X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI03525758X | ||
| 003 | DE-627 | ||
| 005 | 20230429085845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220217s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.02.15.480515 |2 doi | |
| 035 | |a (DE-627)XBI03525758X | ||
| 035 | |a (biorXiv)10.1101/2022.02.15.480515 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Dinnon, Kenneth H. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A model of persistent post SARS-CoV-2 induced lung disease for target identification and testing of therapeutic strategies |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract COVID-19 survivors develop post-acute sequelae of SARS-CoV-2 (PASC), but the mechanistic basis of PASC-associated lung abnormalities suffers from a lack of longitudinal samples. Mouse-adapted SARS-CoV-2 MA10 produces an acute respiratory distress syndrome (ARDS) in mice similar to humans. To investigate PASC pathogenesis, studies of MA10-infected mice were extended from acute disease through clinical recovery. At 15-120 days post-virus clearance, histologic evaluation identified subpleural lesions containing collagen, proliferative fibroblasts, and chronic inflammation with tertiary lymphoid structures. Longitudinal spatial transcriptional profiling identified global reparative and fibrotic pathways dysregulated in diseased regions, similar to human COVID-19. Populations of alveolar intermediate cells, coupled with focal upregulation of pro-fibrotic markers, were identified in persistently diseased regions. Early intervention with antiviral EIDD-2801 reduced chronic disease, and early anti-fibrotic agent (nintedanib) intervention modified early disease severity. This murine model provides opportunities to identify pathways associated with persistent SARS-CoV-2 pulmonary disease and test countermeasures to ameliorate PASC. | ||
| 700 | 1 | |a Leist, Sarah R. |e verfasserin |4 aut | |
| 700 | 1 | |a Okuda, Kenichi |e verfasserin |4 aut | |
| 700 | 1 | |a Dang, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Fritch, Ethan J. |e verfasserin |4 aut | |
| 700 | 1 | |a Gully, Kendra L. |e verfasserin |4 aut | |
| 700 | 1 | |a De la Cruz, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Evangelista, Mia D. |e verfasserin |4 aut | |
| 700 | 1 | |a Asakura, Takanori |e verfasserin |4 aut | |
| 700 | 1 | |a Gilmore, Rodney C. |e verfasserin |4 aut | |
| 700 | 1 | |a Hawkins, Padraig |e verfasserin |4 aut | |
| 700 | 1 | |a Nakano, Satoko |e verfasserin |4 aut | |
| 700 | 1 | |a West, Ande |e verfasserin |4 aut | |
| 700 | 1 | |a Schäfer, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Gralinski, Lisa E. |e verfasserin |4 aut | |
| 700 | 1 | |a Everman, Jamie L. |e verfasserin |4 aut | |
| 700 | 1 | |a Sajuthi, Satria P. |e verfasserin |4 aut | |
| 700 | 1 | |a Zweigart, Mark R. |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a McBride, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Cooley, Michelle R. |e verfasserin |4 aut | |
| 700 | 1 | |a Hines, Jesse B. |e verfasserin |4 aut | |
| 700 | 1 | |a Love, Miriya K. |e verfasserin |4 aut | |
| 700 | 1 | |a Groshong, Steve D. |e verfasserin |4 aut | |
| 700 | 1 | |a VanSchoiack, Alison |e verfasserin |4 aut | |
| 700 | 1 | |a Phelan, Stefan J. |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Hether, Tyler |e verfasserin |4 aut | |
| 700 | 1 | |a Leon, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Zumwalt, Ross E. |e verfasserin |4 aut | |
| 700 | 1 | |a Barton, Lisa M. |e verfasserin |4 aut | |
| 700 | 1 | |a Duval, Eric J. |e verfasserin |4 aut | |
| 700 | 1 | |a Mukhopadhyay, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Stroberg, Edana |e verfasserin |4 aut | |
| 700 | 1 | |a Borczuk, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Thorne, Leigh B. |e verfasserin |4 aut | |
| 700 | 1 | |a Sakthivel, Muthu K. |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Yueh Z. |e verfasserin |4 aut | |
| 700 | 1 | |a Hagood, James S. |e verfasserin |4 aut | |
| 700 | 1 | |a Mock, Jason R. |e verfasserin |4 aut | |
| 700 | 1 | |a Seibold, Max A. |e verfasserin |4 aut | |
| 700 | 1 | |a O’Neal, Wanda K. |e verfasserin |4 aut | |
| 700 | 1 | |a Montgomery, Stephanie A. |e verfasserin |4 aut | |
| 700 | 1 | |a Boucher, Richard C. |e verfasserin |4 aut | |
| 700 | 1 | |a Baric, Ralph S. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 17. Feb. |
| 773 | 1 | 8 | |g year:2022 |g day:17 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.02.15.480515 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 17 |c 02 | ||
| 953 | |2 045F |a 570 | ||